Table I.

Summary of clinical characteristics and treatment course

Patient no.	Age (y) and sex	Cancer diagnosis	Metastatic sites	PD-1 inhibitor	Best tumor response to PD-1	Time (mo) to onset of eruption after PD-1	Clinical features on physical examination	Primary clinical morphologies	PD-1 interrupted or discontinued because of NBP?	Oral steroid course and time	Treatment course of NBP	Treatment response of NBP
1	78, male	Melanoma	Lung	Nivolumab	Complete response	7	Pruritic, erythematous, polymorphic macules and papules	Eczematous and urticarial	Discontinued	10 mg qd for 1 mo, subsequent taper over 1 mo	•Triamcinolone ointment bid prn •Doxycycline 100 mg bid •Nicotinamide 500 mg qd •300 mg omalizumab q4w	Complete resolution after omalizumab
2	78, male	Esophageal adenocarcinoma	Lung and pleura	Pembrolizumab	Stable disease initially, but ultimately progressed	<1	Pruritic, erythematous eruption with urticarial and eczematous features on trunk, extremities, and neck	Urticarial	Not interrupted or discontinued	4-mo steroid taper, maximum dose: 60 mg × 5 d	•Triamcinolone ointment bid prn •Doxycycline 100 mg bid •Nicotinamide 500 mg qd •300 mg omalizumab subq q4w	Complete resolution after omalizumab
3	62, male	Lung adenocarcinoma	Brain, adrenal gland	Pembrolizumab	Stable disease initially, but ultimately progressed	12	Urticarial plaques with central scale on trunk (Fig 2, B)	Urticarial	Discontinued because of disease progression	Steroid taper, maximum dose: 10 mg	•0.05% Betamethasone ointment •Tetracycline 500 mg bid •Nicotinamide 500 mg bid •Rituximab 325 mg/m2 qw for 4 wk	Complete resolution after rituximab
4	58, male	Melanoma	Lung, skin	Pembrolizumab	Decreased tumor burden	7	Diffuse erythematous, pruritic eruption on neck, trunk, and extremities	Urticarial	Discontinued	14-day steroid taper, maximum dose: 10 mg	•Clobetasol 0.05% ointment bid prn •Doxycycline 100 mg bid •Nicotinamide 500 mg bid •Rituximab 325 mg/m2 qw for 4 wk	Complete resolution after rituximab

bid, Twice daily; NBP, nonbullous pemphigoid; PD-1, programmed cell death 1; prn, as needed; q4w, every 4 weeks; qd, every day; qw, every week; subq, subcutaneous.